preval
type
diabet
incid
relat
complic
like
diabet
nephropathi
increas
dramat
worldwid
pandem
diabet
expect
escal
popul
age
obes
rate
continu
soar
common
medic
complic
diabet
includ
rang
progress
chronic
renal
cardiovascular
problem
great
need
clinic
tool
would
enabl
prevent
earli
diagnosi
complic
diabet
nephropathi
one
major
microvascular
complic
type
diabet
lead
caus
endstag
renal
diseas
indic
failur
current
avail
prevent
therapeut
strategi
microalbuminuria
defin
urinari
albumin
excret
mgday
commonli
consid
clinic
sign
renal
dysfunct
earli
predictor
diabet
nephropathi
despit
therapeut
intervent
kidney
function
progress
worsen
mani
diabet
patient
underscor
import
novel
diseasespecif
biomark
renal
renin
angiotensin
system
ra
specif
angiotensin
ii
ang
ii
play
pivot
role
pathogenesi
diabet
nephropathi
ang
ii
angiotensin
convert
enzym
ace
activ
type
diabet
involv
develop
microvascular
macrovascular
complic
diabet
nephropathi
retinopathi
cardiovascular
diseas
addit
glycemia
control
lower
blood
pressur
well
therapeut
approach
aim
block
ra
strategi
known
improv
symptom
diabet
nephropathi
preserv
renal
function
individu
chronic
diseas
due
differ
caus
angiotensin
convert
enzym
new
enzym
within
ra
type
transmembran
glycoprotein
cleav
ctermin
amino
acid
ang
ii
form
ang
play
integr
role
protect
renal
damag
cardiovascular
diseas
administr
inhibitor
increas
albuminuria
mesangi
patholog
fibronectin
deposit
diabet
mice
deliveri
form
recombin
protein
viru
amelior
progress
diabetesrel
complic
nephropathi
retinopathi
addit
urinari
elev
patient
diabet
nephropathi
renal
diseas
renal
transplant
suggest
possibl
role
urinari
noninvas
diseas
biomark
disintegrin
metalloproteas
adam
also
known
tumor
necrosi
factor
enzym
tace
involv
ectodomain
shed
sever
membran
bound
protein
includ
ectodomain
shed
human
embryon
kidney
cell
airway
epitheli
cell
loss
tissu
inhibitor
metalloproteinas
endogen
inhibitor
shown
exacerb
diabet
nephropathi
accumul
evid
suggest
thiazolidinedion
tzd
exhibit
renoprotect
effect
tzd
synthet
ligand
high
affin
toward
isoform
peroxisom
prolifer
activ
receptor
tzd
use
among
first
line
choic
medic
control
hyperglycemia
type
diabet
patient
although
tzd
effect
glycem
control
metaanalysi
suggest
also
increas
risk
macrovascular
complic
reason
use
tzd
restrict
unit
state
favor
less
aggress
treatment
option
clinic
studi
reveal
chronic
treatment
tzd
rosiglitazon
markedli
reduc
urinari
albumin
excret
type
diabet
patient
addit
tzd
modul
ra
particular
ace
ang
ii
receptor
ang
ang
ii
level
howev
effect
tzd
investig
beforeour
central
hypothesi
renal
upregul
combat
detriment
effect
enhanc
ang
ii
earli
stage
diabet
kidney
damag
ang
ii
known
activ
redistribut
caus
shed
renal
tubul
urin
loss
renal
function
lead
increas
renal
injuri
revers
antidiabet
medic
rosiglitazon
result
reduc
renal
express
consequ
decreas
urinari
level
improv
renal
function
male
dbdb
diabet
mice
background
strain
leprdbj
agematch
nondiabet
lean
control
mice
dbm
obtain
jackson
laboratori
bar
harbor
usa
mice
hous
individu
free
access
food
water
hour
lightdark
cycl
six
week
old
mice
randomli
assign
four
treatment
group
control
group
fed
normal
chow
control
group
fed
rosiglitazon
diet
mgkgday
lkt
laboratori
mn
usa
dbdb
group
fed
normal
chow
dbdb
group
fed
rosiglitazon
diet
mgkgday
mice
monitor
weekli
blood
glucos
bodi
weight
food
intak
water
intak
urin
output
period
eight
week
bodi
composit
measur
consciou
mice
use
magnet
reson
spectroscopi
echo
medic
system
houston
tx
usa
treatment
mice
euthan
decapit
trunk
blood
collect
icechil
heparin
tube
blood
centrifug
minut
plasma
separ
aliquot
store
tissu
remov
mice
frozen
liquid
nitrogen
store
experiment
procedur
approv
wright
state
univers
anim
care
use
committe
blood
glucos
test
strip
freestyl
blood
glucos
monitor
system
abbott
ca
usa
use
determin
whole
blood
glucos
level
drop
tail
blood
collect
midday
interv
thereaft
indic
glucos
toler
test
mice
fast
overnight
h
inject
glucos
mgkg
ip
blood
sampl
collect
heparin
capillari
tube
tip
tail
min
glucos
inject
dilut
lysi
reagent
roch
diagnost
usa
glucos
concentr
determin
colorimetr
use
glucos
oxidaseperoxidas
reagent
kit
sigma
mo
usa
sampl
incub
assay
reagent
min
reaction
stop
ad
n
measur
nm
use
fusion
packard
plate
reader
valu
express
mgdl
area
glucos
toler
curv
min
carri
use
prism
softwar
mice
place
individu
metabol
cage
urin
collect
free
access
food
water
urin
specimen
collect
everi
hour
kept
collect
period
complet
prevent
protein
degrad
total
proteas
inhibitor
roch
diagnost
usa
ad
collect
tube
collect
period
urin
sampl
centrifug
min
remov
debri
supernat
aliquot
store
later
use
quantit
urinari
albumin
measur
use
mous
elisa
kit
purchas
bethyl
laboratori
montgomeri
tx
usa
urinari
glucos
excret
measur
urin
sampl
use
glucos
oxidaseperoxidas
reagent
kit
describ
urinari
creatinin
measur
urin
sampl
use
kit
purchas
quidel
san
diego
ca
usa
final
absorb
read
nm
fusion
packard
plate
reader
mice
anaesthet
perfus
transcardi
ice
cold
pb
formalin
perfus
kidney
dehydr
embed
paraffin
section
thick
mount
glass
slide
paraffin
section
stain
period
acidschiff
pa
masson
trichrom
examin
light
microscopi
immunofluoresc
kidney
section
incub
goat
r
system
mn
usa
rabbit
enzo
life
scienc
ny
usa
goat
antinephrin
r
system
primari
antibodi
follow
incub
donkey
antigoat
antirabbit
secondari
antibodi
jackson
immunoresearch
pa
usa
doubl
stain
donkey
antigoat
fluoresceinconjug
secondari
antibodi
jackson
immunoresearch
pa
usa
use
imag
captur
use
confoc
microscop
olympu
pa
usa
metamorph
softwar
molecular
devic
ca
usa
use
quantit
renal
urinari
protein
express
determin
use
western
blot
analysi
kidney
homogen
complet
lysism
edtafre
buffer
roch
appli
scienc
usa
contain
mmoll
pmsf
kidney
lysat
protein
urin
sampl
adjust
creatinin
separ
sdspage
gel
electroblot
pvdf
membran
millipor
usa
block
hour
membran
incub
goat
antimous
rabbit
goat
santa
cruz
biotechnolog
primari
antibodi
overnight
follow
incub
hrpconjug
donkey
antigoat
r
system
usa
donkey
antirabbit
jackson
immunoresearch
secondari
antibodi
signal
detect
use
supersign
chemiluminesc
substrat
thermo
scientif
il
usa
visual
fujifilm
imag
analyz
la
imag
quant
ca
usa
ace
activ
measur
use
assay
kit
purchas
alpco
diagnost
ltd
briefli
plasma
incub
hepe
buffer
ph
contain
synthet
substrat
hippuryl
glycin
glycin
hipglygli
min
incub
reaction
termin
ad
n
hydrochlor
acid
liber
hippur
acid
due
ace
activ
sampl
separ
unreact
substrat
addit
ml
scintil
fluid
measur
ace
activ
express
unitsl
urinari
renal
plasma
activ
measur
use
synthet
fluorogen
substrat
mcaapk
dnp
biomol
intern
ny
usa
modif
sampl
protein
incub
reaction
buffer
mm
tri
mm
mm
lisinopril
mcaapk
dnp
h
fluoresc
measur
excit
nm
emiss
nm
use
fusion
packard
plate
reader
confirm
presenc
activ
urin
matrix
assist
laser
desorptionion
maldi
mass
spectrometri
use
describ
modif
urin
incub
h
mm
me
buffer
ph
contain
ang
ii
mm
pmsf
bestatin
reaction
stop
acidif
trifluoroacet
acid
tfa
final
concentr
peptid
purifi
use
ziptip
millipor
usa
mass
spectra
obtain
use
autoflex
iii
smartbeam
maldi
timeofflight
tof
tof
instrument
bruker
dalton
usa
oper
posit
polar
reflectron
mode
total
laser
shot
acquir
randomli
spot
rang
mz
laser
frequenc
hz
spectra
mass
calibr
use
bruker
peptid
calibr
standard
ii
sampl
measur
mous
metabol
phenotyp
centr
cincinnati
oh
usa
plasma
triglycerid
measur
use
commerci
avail
assay
kit
randox
laboratori
uk
plasma
adiponectin
concentr
measur
mous
adiponectin
elisa
kit
millipor
st
charl
mi
usa
plasma
level
insulin
glucagon
measur
use
map
mous
metabol
hormon
magnet
bead
panel
absorb
measur
use
luminex
millipor
austin
tx
plasma
level
calcul
use
standard
provid
luminex
kit
statist
analysi
perform
use
graphpad
prism
statistica
softwar
data
express
mean
sem
unpair
student
ttest
use
evalu
differ
two
group
two
group
oneway
anova
use
differ
blood
glucos
assess
repeat
measur
twoway
anova
follow
bonferroni
multipl
comparison
test
valu
p
consid
statist
signific
compar
control
mice
sixweek
old
dbdb
diabet
mice
exhibit
significantli
higher
blood
glucos
level
consist
increas
throughout
studi
period
figur
shown
figur
chronic
treatment
dbdb
mice
rosiglitazon
significantli
decreas
blood
glucos
one
week
normal
hyperglycemia
throughout
eightweek
durat
treatment
use
intraperiton
glucos
toler
test
dbdb
mice
show
impair
glucos
util
compar
agematch
control
mice
significantli
improv
rosiglitazonetr
dbdb
mice
figur
c
effect
observ
lean
control
mice
treat
rosiglitazon
summar
tabl
bodi
weight
absolut
bodi
fat
food
intak
water
intak
urin
volum
dbdb
mice
consist
increas
age
compar
control
mice
control
mice
treat
rosiglitazon
addit
plasma
insulin
glucagon
triglycerid
glucos
level
significantli
increas
dbdb
mice
compar
control
mice
control
mice
treat
rosiglitazon
plasma
adiponectin
significantli
decreas
p
chronic
treatment
dbdb
mice
rosiglitazon
demonstr
signific
increas
bodi
weight
absolut
bodi
fat
compar
untreat
dbdb
mice
food
intak
differ
furthermor
rosiglitazon
treatment
dbdb
mice
result
signific
decreas
water
intak
urin
volum
similar
level
observ
control
mice
contrast
treatment
dbdb
mice
rosiglitazon
increas
plasma
adiponectin
level
decreas
glucagon
triglycerid
glucos
level
effect
plasma
insulin
level
significantli
higher
urinari
glucos
excret
dbdb
mice
compar
control
mice
chronic
treatment
dbdb
mice
rosiglitazon
significantli
decreas
urinari
glucos
excret
compar
untreat
dbdb
mice
p
figur
figur
illustr
signific
differ
urinari
albumin
excret
dbdb
mice
control
mice
progress
diseas
led
worsen
albuminuria
chronic
treatment
rosiglitazon
significantli
amelior
urinari
albumin
excret
dbdb
mice
two
week
treatment
p
reduct
urinari
albumin
maintain
throughout
durat
studi
glomerular
tuft
dbdb
mice
reveal
signific
increas
mesangi
expans
surfac
area
significantli
reduc
treatment
rosiglitazon
p
figur
addit
renal
fibrosi
dbdb
mice
significantli
decreas
follow
treatment
rosiglitazon
p
figur
immunofluoresc
show
protein
express
nephrin
glomerular
decreas
kidney
dbdb
mice
tubular
increas
figur
express
profil
revers
glomerular
nephrin
rosiglitazon
treat
dbdb
mice
effect
tubular
western
blot
analysi
detect
strong
immunoreact
band
kda
urin
dbdb
mice
figur
excret
level
significantli
higher
dbdb
mice
rel
control
mice
treat
dbdb
mice
similarli
renal
protein
express
kda
increas
untreat
dbdb
mice
compar
control
mice
figur
howev
signific
differ
renal
protein
express
rosiglitazon
treat
untreat
dbdb
mice
figur
express
renal
follow
express
profil
ident
urinari
level
increas
dbdb
mice
revers
rosiglitazon
treatment
figur
renal
protein
express
significantli
decreas
untreat
treat
dbdb
mice
compar
control
mice
figur
signific
increas
urinari
renal
activ
dbdb
mice
compar
lean
control
mice
figur
b
p
chronic
treatment
rosiglitazon
significantli
reduc
urinari
activ
treat
dbdb
mice
compar
untreat
dbdb
mice
figur
howev
treatment
rosiglitazon
signific
effect
renal
activ
treat
dbdb
mice
compar
untreat
dbdb
mice
figur
quantit
estim
enzym
activ
show
detect
plasma
activ
control
dbdb
mice
contrast
ace
activ
detect
plasma
markedli
increas
untreat
treat
dbdb
mice
figur
presenc
urinari
activ
confirm
use
sensit
maldi
ms
approach
urin
sampl
incub
natur
substrat
ang
ii
format
ang
use
index
activ
urinari
ang
format
dbdb
mice
elev
compar
control
treatment
rosiglitazon
restor
activ
control
level
figur
format
urinari
ang
attribut
sinc
reduc
presenc
specif
inhibitor
figur
chemic
natur
gener
peptid
verifi
msm
show
msm
spectrum
ang
gener
enzymat
urin
ident
msm
spectrum
synthet
ang
spike
urin
reaction
mixtur
figur
relationship
urinari
excret
urinari
glucos
excret
major
metabol
risk
factor
includ
blood
glucos
plasma
glucagon
lipid
concentr
investig
dbdb
diabet
mice
linear
regress
analysi
show
signific
posit
correl
urinari
activ
albumin
excret
plasma
glucagon
plasma
triglycerid
blood
glucos
figur
studi
first
demonstr
shed
renal
urin
increas
dbdb
diabet
mice
urinari
excret
correl
posit
progress
diabet
renal
injuri
repres
progress
albuminuria
mesangi
matrix
expans
renal
fibrosi
overactiv
ra
diabet
especi
ang
ii
ace
lead
hypertens
fluid
retent
inflamm
caus
renal
vascular
endstag
diseas
long
term
ang
ii
play
crucial
role
pathogenesi
progress
diabet
renal
diseas
affect
intraglomerular
capillari
pressur
podocyt
skeleton
compon
slit
diaphragm
lead
glomerular
sclerosi
microalbuminuria
evid
delet
lead
develop
ang
ii
depend
renal
damag
suggest
renoprotect
target
diabet
abil
inactiv
ang
ii
gener
put
reno
cardioprotect
metabolit
ang
suggest
import
particip
cardiovascular
homeostasi
inde
found
activ
renal
dbdb
mice
like
part
mechan
compens
elev
ang
ii
level
moreov
result
demonstr
proteas
known
involv
ectodomain
shed
sever
integr
protein
includ
ace
significantli
upregul
kidney
dbdb
mice
accordingli
treatment
ang
ii
result
enhanc
accumul
renal
studi
also
first
report
show
upregul
renal
dbdb
mice
moreov
renal
express
significantli
reduc
support
earlier
find
loss
endogen
inhibitor
exacerb
diabet
nephropathi
base
data
postul
earli
stage
kidney
damag
renal
sheddas
activ
increas
event
high
circul
ang
ii
express
renal
reduc
consensu
hypothesi
immunostain
result
demonstr
coloc
tubular
diabet
kidney
consequ
due
action
proteolyt
activ
form
kidney
shed
urin
dbdb
diabet
mice
thu
loss
renoprotect
enzym
could
contribut
kidney
damag
one
primari
goal
manag
patient
type
diabet
prevent
delay
develop
diabet
renal
diseas
hyperglycemia
lead
nephropathi
variou
mechan
increas
endotheli
cell
permeabl
albumin
hypertrophi
thicken
basement
membran
observ
decreas
slit
diaphragm
associ
protein
nephrin
glomeruli
dbdb
mice
hypothes
loss
nephrin
slit
pore
may
result
enhanc
passag
albumin
urin
consist
previou
studi
five
week
age
dbdb
mice
exhibit
hyperglycemia
well
microalbuminuria
previou
studi
demonstr
blood
pressur
dbdb
mice
start
rise
eleven
week
age
therefor
propos
kidney
damag
dbdb
mice
initi
trigger
hyperglycemia
increas
age
diseas
progress
kidney
function
deterior
result
signific
rise
albuminuria
mesangi
expans
renal
fibrosi
retrospect
clinic
studi
suggest
strict
control
hyperglycemia
depreci
progress
diabet
nephropathi
cardiovascular
complic
end
explor
effect
normal
glycemia
rosiglitazon
kidney
function
renal
shed
express
dbdb
mice
observ
one
week
treatment
dbdb
mice
signific
declin
blood
glucos
level
normal
level
associ
decreas
urinari
albumin
attenu
renal
patholog
end
studi
period
find
clearli
demonstr
signific
glycem
control
prevent
diabet
renal
injuri
treatment
rosiglitazon
attenu
urinari
protein
excret
activ
effect
renal
treat
dbdb
mice
compar
untreat
dbdb
mice
unchang
level
renoprotect
tubular
might
complement
posit
effect
treatment
rosiglitazon
diabet
kidney
addit
rosiglitazon
markedli
attenu
renal
dbdb
mice
thu
rosiglitazon
treatment
may
impart
renoprotect
via
attenu
shed
possibl
direct
influenc
interestingli
treatment
rosiglitazon
effect
suggest
hyperglycemia
control
addit
convent
fluorogen
assay
urinari
activ
verifi
ms
known
high
sensit
specif
accuraci
agreement
western
blot
result
enzymat
test
system
confirm
urinari
activ
increas
significantli
dbdb
mice
compar
lean
control
contrast
rosiglitazon
treatment
significantli
attenu
urinari
activ
dbdb
mice
moreov
plasma
ace
level
significantli
reduc
treat
dbdb
mice
support
hypothesi
renoprotect
effect
rosiglitazon
could
partli
mediat
influenc
ra
investig
sourc
urin
measur
activ
plasma
kidney
dbdb
mice
activ
previous
observ
sheep
serum
plasma
diabet
rodent
model
howev
plasma
activ
detect
normal
healthi
subject
turn
latter
attribut
effect
presenc
endogen
inhibitor
anoth
studi
show
elev
serum
activ
type
diabet
patient
macro
microvascular
complic
reason
behind
dispar
might
differ
speci
type
substrat
use
incub
time
hour
method
adopt
concurr
previou
find
found
neither
detect
plasma
activ
control
dbdb
mice
significantli
elev
activ
kidney
dbdb
mice
addit
clinic
data
ckd
diabet
renal
transplant
patient
also
support
conclus
kidney
plasma
sourc
urinari
thu
urinari
could
promis
noninvas
biomark
assess
renal
function
diabet
patholog
determin
level
microalbuminuria
still
clinic
use
diagnosi
prognosi
diabet
nephropathi
although
blood
pressur
control
effect
prevent
onset
progress
microalbuminuria
macroalbuminuria
type
diabet
patient
prevent
develop
end
stage
renal
diseas
shown
advanc
trial
therefor
need
sensit
specif
urinari
marker
earli
reliabl
predict
kidney
diseas
previou
studi
human
suggest
ra
compon
urinari
angiotensinogen
determin
kidney
diseas
diabet
well
ckd
patient
rodent
model
ckd
pathophysiolog
chang
associ
increas
overexpress
urinari
ace
suggest
enzym
could
use
biolog
urinari
marker
ckd
moreov
ace
found
human
urin
associ
hypertens
propos
urinari
use
potenti
marker
diabet
nephropathi
result
show
urinari
activ
elev
dbdb
mice
compar
control
mice
persist
increas
throughout
studi
period
eight
wk
excret
urinari
albumin
follow
trend
strong
posit
correl
observ
urinari
activ
albumin
excret
among
group
throughout
experi
find
consist
recent
studi
compar
urinari
albumin
excret
human
patient
interestingli
plasma
abnorm
glucos
glucagon
triglycerid
seen
dbdb
mice
demonstr
signific
posit
correl
urinari
correl
urinari
excret
wellestablish
plasma
risk
factor
diabet
triglycerid
glucagon
suggest
urinari
novel
surrog
marker
diabet
base
result
tempt
hypothes
urinari
independ
risk
factor
predict
earli
onset
diabet
relat
complic
highrisk
patient
conclus
find
suggest
rosiglitazon
impart
renoprotect
least
partial
decreas
renal
shed
dbdb
mice
conjunct
studi
field
urinari
biomark
metabol
diseas
result
suggest
promis
urinari
biomark
detect
earli
sign
kidney
diseas
